4
H index
0
i10 index
43
Citations
Office of Health Economics | 4 H index 0 i10 index 43 Citations RESEARCH PRODUCTION: 4 Articles 21 Papers RESEARCH ACTIVITY: 7 years (2014 - 2021). See details. MORE DETAILS IN: ABOUT THIS REPORT: Permalink: http://citec.repec.org/pco941 |
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Amanda Megan Cole. | Is cited by: | Cites to: |
Journals with more than one article published | # docs |
---|---|
Applied Health Economics and Health Policy | 2 |
Working Papers Series with more than one paper published | # docs |
---|---|
Briefing / Office of Health Economics | 4 |
Year | Title of citing document |
---|---|
2023 | Open and inclusive: fair processes for financing universal health coverage. (2023). Kurowski, Christoph. In: LSE Research Online Documents on Economics. RePEc:ehl:lserod:119795. Full description at Econpapers || Download paper |
2023 | 10 Years of AMNOG: What is the Willingness-to-Pay for Pharmaceuticals in Germany?. (2023). Stargardt, Tom ; Bussgen, Melanie. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:21:y:2023:i:5:d:10.1007_s40258-023-00815-7. Full description at Econpapers || Download paper |
Year | Title | Type | Cited |
---|---|---|---|
2016 | How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2016 | “New Age” Decision Making in HTA: Is It Applicable in Asia? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2019 | Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2019 | Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación? In: Briefing. [Full Text][Citation analysis] | paper | 0 |
2015 | Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices? In: Consulting Report. [Full Text][Citation analysis] | paper | 3 |
2015 | Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK In: Consulting Report. [Full Text][Citation analysis] | paper | 1 |
2015 | Data Governance Arrangements for Real-World Evidence In: Consulting Report. [Full Text][Citation analysis] | paper | 1 |
2016 | Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2017 | Data Governance Arrangements for Real-World Evidence: South Korea In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2018 | Barriers to Uptake of Minimal Access Surgery in the United Kingdom In: Consulting Report. [Full Text][Citation analysis] | paper | 2 |
2018 | The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries In: Consulting Report. [Full Text][Citation analysis] | paper | 5 |
2018 | Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation In: Consulting Report. [Full Text][Citation analysis] | paper | 1 |
2020 | Indication-Based Pricing (IBP) Consultation Report In: Consulting Report. [Full Text][Citation analysis] | paper | 2 |
2020 | NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access? In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2021 | Payment Models for Multi-Indication Therapies In: Consulting Report. [Full Text][Citation analysis] | paper | 0 |
2016 | A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications In: Research Paper. [Full Text][Citation analysis] | paper | 4 |
2016 | An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’ In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2018 | Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals In: Research Paper. [Full Text][Citation analysis] | paper | 7 |
2019 | Making Outcome-Based Payment a Reality in the NHS In: Research Paper. [Full Text][Citation analysis] | paper | 6 |
2019 | Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2021 | Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations In: Research Paper. [Full Text][Citation analysis] | paper | 0 |
2014 | Are the UK Systems of Innovation and Evaluation of Medical Devices Compatible? The Role of NICE’s Medical Technologies Evaluation Programme (MTEP) In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 2 |
2017 | A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact? In: Applied Health Economics and Health Policy. [Full Text][Citation analysis] | article | 4 |
2018 | Valuing EQ-5D-5L health states ‘in context’ using a discrete choice experiment In: The European Journal of Health Economics. [Full Text][Citation analysis] | article | 4 |
2020 | Outcome-Based Payment Schemes: What Outcomes Do Patients with Cancer Value? In: The Patient: Patient-Centered Outcomes Research. [Full Text][Citation analysis] | article | 1 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated December, 10 2023. Contact: CitEc Team